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ABSTRACT 
Intravenous glycyrrhizin has been used in 
Japan for the treatment of chronic hepati- 
tis for >20 years, although only a few re- 
ports of its pharmacokinetic profile after 
multiple intravenous doses in small num- 
bers of Japanese patients have been pub- 
lished. The present study compared these 
Japanese data against the pharmacokinetic 
characteristics of glycyrrhizin after single 
and multiple intravenous doses in 3.5 Eu- 
ropean patients with chronic hepatitis C 
infection. We administered 80, 160, or 240 
mg glycyrrhizin 3 times/wk or 200 mg 
glycyrrhizin 6 timesiwk for 4 weeks. 
Twenty-four-hour pharmacokinetic as- 
sessments were performed on day I and 
on or around day 14. Glycyrrhizin levels 
were determined by high-performance liq- 
uid chromatography. The mean (+ SD) vol- 
ume of distribution at steady state on day 
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1 in the 80-, 160-, 200-, and 240-mg groups 
were67+- ll,62+ 13,54+7,and66*8 
mL/kg, respectively. The respective termi- 
nal elimination half-lives on day 1 were 
7.7 + 2.8, 10.1 f 1.4, 9.0 + 2.3, and 8.6 t 
2.1 hours. The area under the curve (AUC) 
increased linearly with doses 5200 mg 
(r = 0.67; P < 0.001). No significant dif- 
ferences between day 1 and day 14 were 
found in any dose group, with the excep- 
tion of AUC in the 200-mg group, which 
was significantly higher on day 14 com- 
pared with day 1 (P = 0.03). Comparing 
the European and Japanese data, the mean 
(k SD) AUC was 289 & 244 kg/h per mL 
for the former and 402 + 372 kg/h per mL 
for the latter; the half-life was 8.2 f 2.6 
versus 8.8 + 9.0 hours; and the total clear- 
ance was 7.6 +- 3.6 versus 8.5 f 5.7 mL/h 
per kg. Thus our pharmacokinetic data are 
comparable to those from Japan. Gly- 
cyrrhizin’s pharmacokinetics are linear up 
to 200 mg. Drug accumulation is seen af- 
ter 2 weeks of treatment with 200 mg ad- 
ministered 6 times/wk. Key words: phar- 
macokinetics, glycyrrhizin, hepatitis C. 
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INTRODUCTION 
Glycyrrhizin, extracted from the roots of 
the plant Glycyrrhiza glabra (licorice), has 
been used as a treatment for chronic hepa- 
titis in Japan for more than 20 years.’ Ac- 
cording to information from the manufac- 
turer, Minophagen Pharmaceutical Co., 
Ltd. (Tokyo, Japan), tens of millions of 
ampoules of Stronger Neo-Minophagen C@ 
(SNMC) containing 2 mg of glycyrrhizin 
per mL are used annually for this indica- 
tion in Japan. 
Glycyrrhizin is a conjugate of 1 mole- 
cule of glycyrrhetinic acid and 2 mole- 
cules of glucuronic acid (Figure 1). Suzuki 
et a12s3 reported that intravenously admin- 
istered glycyrrhizin lowered serum trans- 
aminase levels significantly in patients 
with chronic hepatitis. Arase et al4 re- 
ported that in Japanese patients with 
chronic hepatitis C infection, normaliza- 
tion of alanine aminotransferase (ALT) 
induced by long-term glycyrrhizin treat- 
ment prevented development of hepato- 
cellular carcinoma. 
Intravenously administered glycyrrhizin 
is metabolized in the liver by lysosomal 
fi-n-glucuronidase to 3-mono-glucuronide- 
glycyrrhetinic acid. The metabolite is ex- 
creted with bile into the intestine, where it 
is metabolized by bacteria into glycyr- 
rhetinic acid, which can be reabsorbed (see 
Figure l).s 
A MEDLINE@ search of the literature 
from January 1966 to July 1999 using the 
key words glycyrrhizin(e) and pharmaco- 
kinetics yielded a small number of Japan- 
ese studies involving 510 patients. These 
studies&’ described the pharmacokinetic 
profile of glycyrrhizin after multiple 
doses of a single dose strength in patients 
with acute and chronic hepatitis and cir- 
rhosis of different causes. In these pa- 
tients, total body clearance was inversely 
correlated with serum ALT level (r = -0.7; 
P < 0.05), suggesting a correlation of 
pharmacokinetic variables with hepatic 
function. 
We conducted a Phase I/II clinical trial 
in Europe to evaluate the dose-dependent 
pharmacokinetics, safety, and efficacy of 
glycyrrhizin treatment. The safety and ef- 
ficacy results have been reported else- 
where.‘O The study reported here was per- 
formed to compare the Japanese data with 
the pharmacokinetics of increasing doses 
of glycyrrhizin in European patients. 
OH 
Glycyrrhizin l&beta-glycyrrhetinic acid 
mono-beta-D-glucuronide 
18-beta-glycyrrhetinic acid 
Figure 1. Metabolism of glycyrrhizin after intravenous administration: (1) in the liver, by 
lysosomal P-n-glucuronidase, and (2) in the intestine, by bacterial P-n-glucuronidase. 
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PATIENTS AND METHODS 
Only patients with chronic hepatitis C in- 
fection, with a positive hepatitis C virus 
RNA titer, serum ALT 2 1.5 times the upper 
limit of normal (ULN), and findings on 
liver biopsy consistent with mild to moder- 
ate liver fibrosis or cirrhosis were included. 
Patients were not eligible for inclusion if 
they had other causes of liver disease, de- 
compensated cirrhosis (Child-Pugh score 
>7), or hepatocellular carcinoma. 
The study was conducted according to 
the Declaration of Helsinki and good clin- 
ical practice guidelines. The protocol was 
approved by the medical ethical commit- 
tee of the Erasmus University Hospital 
Rotterdam, and all patients gave their 
written informed consent. 
Study Treatment 
Glycyrrhizin was given as SNMC, a 
clear solution for intravenous use, con- 
sisting of 2 mg glycyrrhizin, 1 mg cys- 
teine, and 20 mg glycine per mL in phys- 
iologic saline solution. Patients received 
SO, 160, or 240 mg intravenous gly- 
cyrrhizin 3 times/wk or 200 mg intra- 
venous glycyrrhizin 6 timeslwk for 4 
weeks. 
The medication administered 3 times/ 
wk was given by drip infusion over 15 to 
20 minutes in a total volume of 220 mL. 
The infusion line was then flushed with 
25 mL sodium chloride (0.9%). The med- 
ication given 6 timesiwk was adminis- 
tered undiluted into a peripheral vein over 
3 to 5 minutes. 
Pharmacokinetic Measurements 
Pharmacokinetic measurements were ob- 
tained on the first day of treatment and on 
or around day 14. Patients were not allowed 
to consume food or drink (except water) af- 
ter 11 PM of the night before pharmacoki- 
netic measurements were to be taken. On 
the days of pharmacokinetic measurements, 
food was allowed 4 hours after administra- 
tion of medication, and water was allowed 
as required. Patients remained semirecum- 
bent from 0.5 hour before until 4 hours af- 
ter receiving medication. 
Blood Sampling 
An indwelling cannula was placed in 1 
arm for blood sampling; medication was ad- 
ministered in the other arm. Before sam- 
pling, -1 mL of blood was discarded. Eth- 
ylenediaminetetraacetic acid-blood samples 
(7 mL) were collected at the following times 
on the days of pharmacokinetic measure- 
ments: before administration of medication 
and at 0,5, 15,45,60,90 minutes and 2,4, 
6, 8, 10, 12, 16, 18, and 24 hours after ad- 
ministration of medication (administration 
of medication was complete at time 0). Sam- 
ples were stored on ice, and plasma was 
separated within 1 hour by centrifugation at 
4’C and 3000~ for 10 minutes. Plasma sam- 
ples were stored at -2O’C until analyzed. 
High-Performance Liquid 
Chromatography 
Plasma samples were analyzed by a val- 
idated high-performance liquid chromato- 
graphic (HPLC) method modified from 
Raggi et al. ” Fifty p,L propylparaben (25 
mg/L internal standard solution) and 2 mL 
methanol were added to 500 pL plasma. 
After mixing and centrifugation, the su- 
pernatant was decanted into another test 
tube and evaporated at 4O’C with flushing 
nitrogen. The residue was dissolved in 
500 pLacetonitrile/citrate ( 180:320) buffer 
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(0.1 mol/L, pH 2.8). After vortexing and 
centrifugation, 20 p,L of the supernatant 
was injected into the HPLC system. The 
extract was separated on a ChromSpher-5 
C8 (Chrompack, Bergen op Zoom, The 
Netherlands) column (200 x 3 mm; 5 km 
particles) with the acetonitrileicitrate 
buffer at a flow of 0.6 mL/min at ambient 
temperatures. Detection was by ultravio- 
let absorption at 250 nm with a diode ar- 
ray detector. 
As validated in our laboratory, the as- 
say was linear over a range from ~0.5 to 
150 mg/L. The limit of quantification was 
0.5 mg/L. Day-to-day variations were 
<2% at concentrations of >30 mg/L and 
~5% in the lower range (-1 mg/L). 
Pharmacokinetic Analysis 
A weighted least-squares regression 
analysis, with l/y2 as a weighting factor for 
each data point, was performed using Top- 
fit version 2.012 to analyze the plasma con- 
centration-time data for each patient. We 
calculated the maximum concentration 
(C,,,), total clearance (Cl,,), volume of 
distribution at steady state (V& area under 
the curve (AUC) from time zero to infinity, 
and terminal elimination half-life (t,,,). 
Data analysis was based on a weighted 
3-compartment disposition model, which 
was deemed the most appropriate model 
based on visual inspection and minimized 
residuals. 
Statistical Analysis 
Statistical analysis was performed us- 
ing Stata 5.0 software (Stata Corporation, 
College Station, Texas). Results are ex- 
pressed as mean + SD. Comparisons be- 
tween groups were conducted using the 
Kruskal-Wallis test; if P < 0.05, the Mann- 
Whitney test was used to perform further 
pairwise comparisons between groups. 
Differences within groups were assessed 
using the Wilcoxon signed rank test. 
Spearman correlation coefficients were 
used. Significance was set at P = 0.05 
(2-sided) for all tests. 
RESULTS 
The baseline characteristics of the patients 
are shown in Table I. The 4 groups were 
comparable in terms of all characteristics 
except baseline ALT value, which was sig- 
nificantly lower in the group receiving 
240 mg 3 times/wk than in the group re- 
ceiving 200 mg 6 times/wk (P = 0.02). 
Figure 2 shows a chromatogram 6 hours 
after a single dose of 200 mg glycyrrhizin. 
Figure 3 shows the mean course of the 
measured plasma concentration on day 1 
and day 14 for the group receiving 200 
mg glycyrrhizin 6 times/wk. The plasma 
concentration of glycyrrhizin declined ac- 
cording to a 3-compartment model. 
The second of the 2 pharmacokinetic 
measurements was performed on day 13 
in 1 patient; day 14 in 27 patients; day 15 
in 2 patients; and day 16 in 3 patients. Re- 
sults for the pharmacokinetic variables are 
shown in Table II. A dose-response rela- 
tionship was found between the C,, and 
AUC. The C,, increased in a log-log plot 
with increasing dosage (day I, r = 0.82, 
P < 0.001; day 14, r = 0.89, P < O.Ol), 
whereas there was no significant deviation 
from linearity. A linear increase in AUC 
with dose was found only for the 80-, 
160-, and 200-mg doses (day 1, r = 0.67, 
P < 0.001; day 14, r = 0.57, P < 0.002). 
The mean (+ SD) Vss on day 1 was be- 
tween 54 rt 7 and 67 f 11 mL/kg; the mean 
Cl,, was between 5.9 f 2.5 and 10.3 * 3.1 
mL/h per kg; and the mean tu2 was be- 
2083 
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Table 1. Baseline characteristics of the 35 patients, by glycyrrhizin dose. 
Dose, mg (No. of Patients) 
80 (8) 160 (7) 240 (7) 200 (13) 
Frequency of 
administration 3 timesiwk 3 timesiwk 3 timesiwk 6 times/wk 
Sex 
Male 6 5 7 II 
Female 2 2 0 2 
Age (Y) 
Mean 47 54 43 50 
Range 35-66 43-60 34-s9 39-70 
Weight (kg) 
Mean 71 78 79 79 
Range Z-107 64-94 62-119 63-109 
Cirrhosis 3 3 3 7 
No cirrhosis 5 4 4 6 
ALT (ULN) 
Mean 3.8 3.6 2.1' 3.9 
95% CI 2.0-5.7 2.0-S. 1 1.8-2.5 2.2-5.7 
ALT = alanine aminotransferase; ULN = upper limit of normal 
*Significantly ~200 mg 6 timesiwk; P = 0.02. 
250- 
200- 
g 150- 
z .- 
s 
2 loo- 
50- 
0 -t-/i L- 
I I I / I I, I / I 
01 2 3 4 5 6 7 8 910 
Minutes 
Figure 2. Chromatogram of a plasma sample obtained 6 hours after a single dose of 200 
mg glycyrrhizin. IS = internal standard; PPB = propylparaben. 
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Figure 3. Mean measured plasma concentration-time profile for the group administered 
200 mg glycyrrhizin on day 1 and day 14. 
tween 7.7 -t 2.8 and 10.1 & 1.4 hours. No 
significant difference was noted on day 1 
and day 14 between dose groups, except 
for the significantly higher AUC in the 200- 
mg group on day 14 compared with day 1 
(P = 0.03). All variables showed a strong 
correlation between day 1 and day 14. 
Table III shows the C&,, and t,,, for cir- 
rhotic and noncirrhotic patients on day 1 
and day 14 after combining all dose groups. 
There were no significant differences be- 
tween cirrhotic and noncirrhotic patients. 
No correlation could be found between 
ALT levels at baseline and Cl,, or t,,,. 
DISCUSSION 
This study reports the pharmacokinetic 
characteristics of increasing doses of intra- 
venous glycyrrhizin after single and multi- 
ple doses in the largest cohort of patients 
(35 patients) studied to date. The variation 
in cInax in the 200-mg group appeared to 
be substantially larger than in the other 3 
groups (Figure 4). An explanation for this 
observation could be that the 200-mg dose 
was administered by manual direct intra- 
venous injection in 3 to 5 minutes while 
the other 3 dosages were administered by 
drip infusion in 15 to 20 minutes; it is likely 
that the slower infusion rate caused a more 
equal administration of glycyrrhizin be- 
tween patients than injection. 
It is possible that different rates of infu- 
sion might affect the dose linearity and 
number of compartments. However, in our 
study, the AUC increased linearly with dose 
between 80 to 200 mg, although the 80- 
and 160-mg doses were administered over 
15 to 20 minutes, and the 200-mg dose was 
2085 
Ta
bl
e 
II.
 
Ph
ar
rn
ac
ok
in
et
ic
 
re
su
lts
, 
by
 d
os
ag
e 
gr
ou
p,
 
on
 d
ay
s 
1 
an
d 
14
. 
80
 m
g 
3 
tim
es
lw
k 
16
0 
m
g
 3
 ti
m
es
/w
k 
24
0 
m
g
 3
 ti
m
es
iw
k 
20
0 
m
g
 6 
tim
es
lw
k 
D
ay
 1
 
D
ay
 1
4 
D
ay
 I 
D
ay
 I
4 
D
ay
 1
 
D
ay
 14
 
D
ay
 
1 
D
ay
 1
4 
(n
 =
 8
) 
(n
= 
7)
 
(n
=7
) 
(n
 =
 7
) 
(n
 =
 7
) 
(n
 
= 
7)
 
(n
=
 1
1)
 
(n
 =
 1
2)
 
C
,,,
 
hW
-f 
42
tt 
14
 
3k
+4
 
70
+1
4 
72
rt:
ii 
10
22
7 
10
62
 
16
 
11
2*
39
 
11
6-
1-
40
 
V,
, 
W
JW
 
67
1I
I 
66
4 
10
 
62
~ 
13
 
57
 
+ 
15
 
66
 
f 
8 
63
 
s 
10
 
54
tl 
53
A 
14
 
AU
C 
(y
g/
h/
m
L)
 
13
8*
76
 
11
2k
37
 
41
5r
t 
IS
6 
46
6*
22
32
 
31
9k
66
 
34
5 
i9
9 
46
8*
21
0 
57
4r
38
9 
Cl
,,,
 
W
Jh
W
 
9.
9 
fr 
3.
3 
10
.8
 
k 
2.
9 
5.
9 
rt 
2.
5 
5.
7 
* 
2.
7 
IO
.3
 
k 
3.
1 
9.
8 
+ 
3.
2 
6.
0 
iz 
2.
6 
5.
5 
* 
2.
6 
‘,,
a 
(h
) 
7.
1 
+ 
2-
8 
6.
2 
iz2
2.
7 
10
.1
 rt 
1.
4 
10
.2
 
f 
1.
6 
8.
6 
rt 
2.
t 
6-
6 
+ 
2.
0 
9.
0 
Ac
t.3
 
9.
1 
k2
.2
 
Va
lu
es
 
ar
e 
ex
pr
es
se
d 
as
 m
ea
n 
A 
SD
. 
%
x 
= 
m
ax
im
um
 c
on
ce
nt
ra
tio
n;
 V
S,
 =
 v
ol
um
e 
of
 d
is
t~
bu
tio
n 
at
 s
te
ad
y 
st
at
e;
 AU
C 
= 
ar
ea
 u
nd
er
 th
e 
cu
rv
e;
 C
l, 
= 
to
ta
l c
le
ar
an
ce
; t
in
 =
 h
al
f-l
ife
. 
T.G.J. VAN ROSSUM ET AL. 
Table III. Total clearance (Cl,J and half-life (t,,,) for patients with chronic hepatitis and 
cirrhosis on days 1 and 14. 
Chronic Hepatitis Cirrhosis 
Day 1 Day 14 Day 1 Day 14 
(n = 19) (n = 17) (n = 14) (n = 16) 
Cl,, WJhkc9 8.3 + 3.0 8.1 f  3.2 7.2 k 4.0 7.1 k4.0 
G/2 (h) 8.2 f. 2.2 7.7 + 2.5 9.7 + 2.3 8.7 f  2.7 
Results are expressed as mean + SD. 
250 
1 
. 
f 
l Day1 
q Day14 
- Median dose, day 1 
. 
a 
O8b 
Dose (mg) 
Figure 4. Calculated maximum concentration (C,,,) per patient per dose on day 1 and 
day 14. 
given over 3 to 5 minutes. The pharmaco- 
kinetic data after both administration rates 
fitted best according to a 3-compartment 
model. So the difference between adminis- 
tration over 3 to 5 minutes or 15 to 20 min- 
utes does not appear to affect dose linear- 
ity or compartmentalization. 
With glycyrrhizin’s half-life of -9 hours, 
a dosing interval of 24 hours might lead 
to some accumulation. Indeed, the AUC 
for the group receiving 200 mg 6 times/wk 
was significantly higher at day 14 compared 
with day 1; after 14 days of treatment, the 
mean (+ SD) glycyrrhizin concentration be- 
fore administration of medication was 7.8 + 
11 .O mg/L. 
Our pharmacokinetic data are based on 
samples taken between 0 minutes and 24 
hours after administration of medication. 
We observed a 3-compartment distribu- 
2087 
tion over the entire period. Tanaka et al6 
investigated the pharmacokinetic profile 
of multiple doses of intravenously admin- 
istered glycyrrhizin 120 mg in 8 patients 
with chronic hepatitis of unreported cause, 
and Yamamura et al’ investigated the same 
regimen in 4 patients with acute hepatitis 
and 6 patients with cirrhosis (5 of 6 cases 
were caused by chronic hepatitis C infec- 
tion). In these studies, samples were taken 
between 2 and 10 hours after drug ad- 
ministration. Over this g-hour period, the 
investigators observed a monoexponen- 
tial decline in glycyrrhizin, as in our study. 
Combining the pharmacokinetic data 
on the 8 patients from Tanaka et al6 and 
the 10 patients from Yamamura et al’ 
yields a mean (+ SD) t,,, of 8.8 f 9.0 
hours, a Cl,“, of 8.5 f 5.7 mL/h per kg, 
and an AUC of 402 f 372 pglh per mL. 
These data obtained after multiple doses 
of glycyrrhizin are comparable to those 
obtained in our study (Table IV). 
The t,,, of glycyrrhizin in 3 healthy vol- 
unteers has been reported as 3.5 hours.‘“*r4 
Yamamura et al’” observed an increase in 
tr,* and a decrease in Cl,Ot among cirrhotic 
patients compared with noncirrhotic pa- 
tients. We found no significant differences 
between cirrhotic and noncirrhotic pa- 
tients (Table III). Cl,O, and ti,? are phar- 
macokinetic parameters that depend on 
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physiologic variables. Therefore it seems 
logical that a decrease in hepatic function 
would lead to a decrease in Cl,,, and an 
increase in t,,2. We did not observe such 
a relationship in the present study, proba- 
bly because patients with severe liver dis- 
ease were excluded. Mean ALT levels be- 
fore the initiation of treatment in the 
Japanese patients were -300 IUIL, much 
higher than our baseline ALT levels of 
-3.5 times the ULN, or 150 IUIL. 
Comparisons of pharmacokinetic data 
between centers should be interpreted cau- 
tiously. Variations in population, degree of 
disease, dose rate and regimen, sampling 
frequency, and duration of observation are 
all capable of influencing study results. 
Given these limitations, we conclude that 
our data corroborate and strengthen those 
from the smaller studies6.’ 
The first phase of the 3-compartment 
model can be explained predominantly by 
the distribution of glycyrrhizin. The VS, 
was -4.5 L/patient, which means that gly- 
cyrrhizin was confined mainly to the vas- 
cular compartment. Glycyrrhizin is not 
taken up in blood cells.‘” The second 
phase can be explained by elimination, 
predominantly through the metabolism 
of glycyrrhizin to 3-mono-glucuronide- 
glycyrrhetinic acid in the liver by lysoso- 
ma1 fi-o-glucuronidase.s The third phase 
Table IV. Japanese and European pharmacokinetic data after multiple doses. 
Japan Europe 
(N = 18) (N = 33) 
AK for 120 mg (pg/h/mL) 402 k 372 289 k 244 
Cl,,,, (mL/h/kg) 8.5 + 5.7 7.6 +- 3.6 
5/2 (h) 8.8 f 9.0 8.2 f 2.6 
Results are expressed as mean + SD. 
AUC = area under the curve; Q, = total clearance; t,!* = half-life. 
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can be explained by an enterohepatic cy- 
cle of glycyrrhizin, which would extend 
the elimination phase.15,16 
CONCLUSIONS 
Glycyrrhizin exhibits linear pharmacoki- 
netics up to 200 mg; steady-state kinetics 
are attained after 2 weeks of 200 mg ad- 
ministered 6 times/wk. Our pharmacoki- 
netic data are comparable to the Japanese 
findings, although we did not find a cor- 
relation between hepatic function and 
pharmacokinetics. This difference may be 
explained by our patients having milder 
liver disease. 
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